Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

Related Articles by Review for PubMed (Select 23110609)

1.

Insulin detemir: a review of its use in the management of diabetes mellitus.

Keating GM.

Drugs. 2012 Dec 3;72(17):2255-87. doi: 10.2165/11470200-000000000-00000. Review.

PMID:
23110609
2.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

4.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
5.

Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus.

Chapman TM, Perry CM.

Drugs. 2004;64(22):2577-95. Review.

PMID:
15516157
6.

Insulin glargine: a systematic review of a long-acting insulin analogue.

Wang F, Carabino JM, Vergara CM.

Clin Ther. 2003 Jun;25(6):1541-77, discussion 1539-40. Review.

PMID:
12860485
7.

Defining the role of insulin detemir in Basal insulin therapy.

Morales J.

Drugs. 2007;67(17):2557-84. Review.

PMID:
18034591
8.

Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis.

Szypowska A, Golicki D, Groele L, PaƄkowska E.

Pol Arch Med Wewn. 2011 Jul-Aug;121(7-8):237-46. Review.

9.

Biphasic insulin aspart 30: literature review of adverse events associated with treatment.

Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R.

Clin Ther. 2005;27 Suppl B:S75-88. Review.

PMID:
16519039
10.

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.

Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005613. Review.

PMID:
17443605
11.

Spotlight on insulin glargine in type 1 and 2 diabetes mellitus.

McKeage K, Goa KL.

Treat Endocrinol. 2002;1(1):55-8. Review.

PMID:
15765621
12.

Insulin detemir: a long-acting insulin product.

Jones MC, Patel M.

Am J Health Syst Pharm. 2006 Dec 15;63(24):2466-72. Review. Erratum in: Am J Health Syst Pharm. 2007 Feb 15;64(4):346.

PMID:
17158694
13.

Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.

Chapman TM, Noble S, Goa KL.

Drugs. 2002;62(13):1945-81. Review. Erratum in: Drugs. 2003;63(5):512..

PMID:
12215068
14.

Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus.

Keating GM.

Drugs. 2013 May;73(6):575-93. doi: 10.1007/s40265-013-0051-1. Review.

PMID:
23620200
15.

Efficacy of biphasic insulin aspart in patients with type 2 diabetes.

Halimi S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G.

Clin Ther. 2005;27 Suppl B:S57-74. Review.

PMID:
16519038
16.

A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.

Frier BM, Russell-Jones D, Heise T.

Diabetes Obes Metab. 2013 Nov;15(11):978-86. doi: 10.1111/dom.12106. Epub 2013 May 1. Review.

PMID:
23551900
17.

Refining basal insulin therapy: what have we learned in the age of analogues?

Devries JH, Nattrass M, Pieber TR.

Diabetes Metab Res Rev. 2007 Sep;23(6):441-54. Review.

PMID:
17668418
18.

Insulin detemir versus insulin glargine for type 2 diabetes mellitus.

Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH.

Cochrane Database Syst Rev. 2011 Jul 6;(7):CD006383. doi: 10.1002/14651858.CD006383.pub2. Review.

PMID:
21735405
19.
20.

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.

Warren E, Weatherley-Jones E, Chilcott J, Beverley C.

Health Technol Assess. 2004 Nov;8(45):iii, 1-57. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk